Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 17 (Suppl 4):iv1–iv62. 2015. View Article : Google Scholar

Nelson CP, Bloom DA, Kinast R, Wei JT and Park JM: Long-term patient reported outcome and satisfaction after oral mucosa graft urethroplasty for hypospadias. J Urol. 174:1075–1078. 2005. View Article : Google Scholar

Luchsinger JA: Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention? J Alzheimers Dis. 20:723–736. 2010. View Article : Google Scholar

Koide S, Koide A and Lipovšek D: Target-binding proteins based on the 10th human fibronectin type III domain (¹⁰Fn3). Methods Enzymol. 503:135–156. 2012. View Article : Google Scholar

Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar

Chen JK, Taipale J, Cooper MK and Beachy PA: Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16:2743–2748. 2002. View Article : Google Scholar

Choi SW, Lee Y, Shin K, Koo H, Kim D, Sa JK, Cho HJ, Shin HM, Lee SJ, Kim H, et al: Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell Death Dis. 12:3742021. View Article : Google Scholar

Golovina VA and Blaustein MP: Spatially and functionally distinct Ca2+ stores in sarcoplasmic and endoplasmic reticulum. Science. 275:1643–1648. 1997. View Article : Google Scholar

van Noort J, Verbrugge S, Goosen N, Dekker C and Dame RT: Dual architectural roles of HU: Formation of flexible hinges and rigid filaments. Proc Natl Acad Sci USA. 101:6969–6974. 2004. View Article : Google Scholar

Chen C, Zhu S, Zhang X, Zhou T, Gu J, Xu Y, Wan Q, Qi X, Chai Y, Liu X, et al: Targeting the synthetic vulnerability of PTEN-deficient glioblastoma cells with MCL1 inhibitors. Mol Cancer Ther. 19:2001–2011. 2020. View Article : Google Scholar

Du L, Zhang Q, Li Y, Li T, Deng Q, Jia Y, Lei K, Kan D, Xie F and Huang S: Research progress on the role of PTEN deletion or mutation in the immune microenvironment of glioblastoma. Front Oncol. 14:14095192024. View Article : Google Scholar

Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y and Huang L: PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol. 104:155–167. 2011. View Article : Google Scholar

Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE and Singh RK: Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65:9004–9011. 2005. View Article : Google Scholar

Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, Yao G, Wang Y, Chen H, Cheng W, et al: Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC Cancer. 18:7462018. View Article : Google Scholar

García-Romero N, Palacín-Aliana I, Esteban-Rubio S, Madurga R, Rius-Rocabert S, Carrión-Navarro J, Presa J, Cuadrado-Castano S, Sánchez-Gómez P, García-Sastre A, et al: Newcastle disease virus (NDV) oncolytic activity in human glioma tumors is dependent on CDKN2A-type I IFN gene cluster codeletion. Cells. 9:14052020. View Article : Google Scholar

Burman B, Pesci G and Zamarin D: Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel). 12:35522020. View Article : Google Scholar

Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B and Csatary CM: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol. 67:83–93. 2004. View Article : Google Scholar

Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, Liu R, Chen W, Tong W, Wei Q, et al: SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 6:3372021. View Article : Google Scholar

Abbott NJ, Rönnbäck L and Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 7:41–53. 2006. View Article : Google Scholar

Jang SH, Jung BK, An YH and Jang H: The phosphatase and tensin homolog gene inserted between NP and P gene of recombinant New castle disease virus oncolytic effect test to glioblastoma cell and xenograft mouse model. Virol J. 19:212022. View Article : Google Scholar

Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H and Iwama T: VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun. 360:553–559. 2007. View Article : Google Scholar

Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, Luthra S, Chandran UR, Beno PV, Smith L, et al: Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA. 110:8644–8649. 2013. View Article : Google Scholar

Lin W, Niu R, Park SM, Zou Y, Kim SS, Xia X, Xing S, Yang Q, Sun X, Yuan Z, et al: IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis. Nat Commun. 14:15782023. View Article : Google Scholar

Spearman C: The method of ‘right and wrong cases’ (constant stimuli) without gauss's formula. Br J Psychol. 2:227–242. 1908.

Kärber G: Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 162:480–483. 1931. View Article : Google Scholar

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

Raftery N and Stevenson NJ: Advances in anti-viral immune defence: Revealing the importance of the IFN JAK/STAT pathway. Cell Mol Life Sci. 74:2525–2535. 2017. View Article : Google Scholar

Zhou S, Wang H, Huang Y, Wu Y and Lin Z: The global change of gene expression pattern caused by PTEN mutation affects the prognosis of glioblastoma. Front Oncol. 12:9525212022. View Article : Google Scholar

Li Y, Liang Y, Sun Z, Xu K, Fan X, Li S, Zhang Z, Jiang T, Liu X and Wang Y: Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging. Neuroradiology. 61:1229–1237. 2019. View Article : Google Scholar

Hernandez J, Bonnedahl J, Eliasson I, Wallensten A, Comstedt P, Johansson A, Granholm S, Melhus A, Olsen B and Drobni M: Globally disseminated human pathogenic Escherichia coli of O25b-ST131 clone, harbouring blaCTX-M-15, found in Glaucous-winged gull at remote Commander Islands, Russia. Environ Microbiol Rep. 2:329–332. 2010. View Article : Google Scholar

Strzalka W and Ziemienowicz A: Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Ann Bot. 107:1127–1140. 2011. View Article : Google Scholar

Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA and Goldberg GI: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 264:17213–17221. 1989. View Article : Google Scholar

Yang JM, Schiapparelli P, Nguyen HN, Igarashi A, Zhang Q, Abbadi S, Amzel LM, Sesaki H, Quiñones-Hinojosa A and Iijima M: Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene. 36:3673–3685. 2017. View Article : Google Scholar

Cheung M and Testa JR: Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets. 13:234–244. 2013. View Article : Google Scholar

Fine HA: Radiotherapy plus adjuvant temozolomide for the treatment of glioblastoma-a paradigm shift. Nat Clin Pract Oncol. 2:334–335. 2005. View Article : Google Scholar

Colón-Thillet R, Jerome KR and Stone D: Optimization of AAV vectors to target persistent viral reservoirs. Virol J. 18:852021. View Article : Google Scholar

Ferguson MS, Lemoine NR and Wang Y: Systemic delivery of oncolytic viruses: Hopes and hurdles. Adv Virol. 2012:8056292012. View Article : Google Scholar

Belete TM: The current status of gene therapy for the treatment of cancer. Biologics. 15:67–77. 2021.

Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, et al: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 13:221–228. 2006. View Article : Google Scholar

Lemos de Matos A, Franco LS and McFadden G: Oncolytic viruses and the immune system: The dynamic duo. Mol Ther Methods Clin Dev. 17:349–358. 2020. View Article : Google Scholar

Li X, Sun X, Wang B, Li Y and Tong J: Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci. 18:1007712023. View Article : Google Scholar

Lin D, Shen Y and Liang T: Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduct Target Ther. 8:1562023. View Article : Google Scholar

Zamarin D and Palese P: Oncolytic Newcastle disease virus for cancer therapy: Old challenges and new directions. Future Microbiol. 7:347–367. 2012. View Article : Google Scholar

Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, et al: Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 158:1142042023. View Article : Google Scholar

Zhang P, Meng X, Liu L, Li S, Li Y, Ali S, Li S, Xiong J, Liu X, Li S, et al: Identification of the prognostic signatures of glioma with different PTEN status. Front Oncol. 11:6333572021. View Article : Google Scholar

Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH and Baker SJ: Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res. 64:7773–7779. 2004. View Article : Google Scholar

Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L and Song S: PTEN gene mutations correlate to poor prognosis in glioma patients: A meta-analysis. Onco Targets Ther. 9:3485–3492. 2016.

Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM and Greager JA: Newcastle disease virus selectively kills human tumor cells. J Surg Res. 52:448–453. 1992. View Article : Google Scholar

Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope H, Yu M, et al: Author correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2:9682018. View Article : Google Scholar

Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, Xiao W and Ma E: Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci. 90:962–967. 2012. View Article : Google Scholar

Pardridge WM: Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 32:1959–1972. 2012. View Article : Google Scholar

Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar

Huang X, You L, Nepovimova E, Psotka M, Malinak D, Valko M, Sivak L, Korabecny J, Heger Z, Adam V, et al: Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK). J Enzyme Inhib Med Chem. 38:22372092023. View Article : Google Scholar

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell. 170:605–635. 2017. View Article : Google Scholar

Kilkenny C, Browne WJ, Cuthi I, Emerson M and Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Vet Clin Pathol. 41:27–31. 2012. View Article : Google Scholar